PARD Stock Price, Chart, Stats & News

Poniard Pharmaceuticals, Inc.
Save
Poniard Pharmaceuticals, Inc. (PARD) does not currently pay a dividend.
150
Market cap
–
Current P/E
–
Forward P/E
PARD chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and market introduction of cancer treatments. Its flagship product candidate, Picoplatin, is a platinum-based therapy targeting various cancer types, such as small cell lung, colorectal, prostate, and ovarian cancers. The company has advanced Picoplatin through several clinical stages, including a pivotal Phase III SPEAR trial for small cell lung cancer patients in a second-line treatment setting.
Similar securities
Based on sector and market capitalization
Report issue





